Preclinical studies have shown that the use of recombinant NDV to deliver P53-encoded tumor suppressor proteins effectively inhibited the growth and invasion of GBM cells in vitro and in vivo (Fan et al., 2018). Here, TP53 is linked to glioblastoma.